Blueprint Medicines President, Research and Development Fouad Namouni receives $6.7M in 2020
Blueprint Medicines reports 2020 executive compensation
By ExecPay News
Published: April 21, 2021
Blueprint Medicines reported fiscal year 2020 executive compensation information on April 21, 2021.
In 2020, five executives at Blueprint Medicines received on average a compensation package of $3.9M, a 1% decrease compared to previous year.
Average pay of disclosed executives at Blueprint Medicines
Fouad Namouni, President, Research and Development, received $6.7M in total. 50% of Namouni's compensation, or $3.3M, was in option awards. Namouni also received $103K in non-equity incentive plan, $186K in salary, as well as $3.1M in stock awards.
For fiscal year 2020, the median employee pay was $332,124 at Blueprint Medicines. Therefore, the ratio of Fouad Namouni's pay to the median employee pay was 20 to one.
Jeffrey W. Albers, Chief Executive Officer, received a compensation package of $6.3M, which decreased by 32% compared to previous year. 43% of the compensation package, or $2.7M, was in option awards.
Kathryn Haviland, Chief Operating Officer, earned $2.4M in 2020, a 24% decrease compared to previous year.
Tracey L. McCain, Chief Legal and Compliance Officer, received $2.3M in 2020, which decreases by 19% compared to 2019.
Michael Landsittel, Chief Financial Officer, earned $2M in 2020, a 3% increase compared to previous year.
Related executives
Jeffrey Albers
Blueprint Medicines
Chief Executive Officer
Michael Landsittel
Blueprint Medicines
Chief Financial Officer
Fouad Namouni
Blueprint Medicines
President, Research and Development
Kathryn Haviland
Blueprint Medicines
Chief Operating Officer
Tracey McCain
Blueprint Medicines
Chief Legal and Compliance Officer
You may also like
Source: SEC filing on April 21, 2021.